Feline primary erythrocytosis: a multicentre case series of 18 cats by Darcy, H et al.
  
 
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the author’s accepted manuscript of an article published in Journal of Feline Medicine 
and Surgery. 
The final publication is available at SAGE Journals via 
https://doi.org/10.1177%2F1098612X17750333.  
The full details of the published version of the article are as follows: 
 
TITLE: Feline primary erythrocytosis: a multicentre case series of 18 cats 
AUTHORS: Hannah Darcy, Katherine Simpson, Isuru Gajanayake, Mayank Seth, Yvonne 
McGrotty, Balazs Szladovits, Barbara Glanemann 
JOURNAL TITLE: Journal of Feline Medicine and Surgery. 
PUBLICATION DATE: 24 January 2018 (online) 
PUBLISHER: SAGE Publications 
DOI: 10.1177%2F1098612X17750333 
 
Feline primary erythrocytosis: a multicentre case series of 18 cats 1 
 2 
Hannah Darcy1, Katherine Simpson2, Isuru Gajanayake3, Mayank Seth4, Yvonne McGrotty5, Balazs 3 
Szladovits6, Barbara Glanemann1 4 
 5 
1 Queen Mother Hospital for Animals, Department of Clinical Science and Services, Royal Veterinary 6 
College, North Mymms, Hertfordshire, AL9 7TA, UK 7 
2 Goddard Veterinary Group, Mandeville Veterinary Hospital, 15 Mandeville Road, Northolt, UB5 8 
5HD, UK  9 
3 Willows Veterinary Centre and Referral Service, Highlands Road, Shirley, Solihull, West Midlands, 10 
B90 4NH, UK 11 
4 Centre for Small Animal Studies, Animal Health Trust, Lanwades Park, Kentford, Newmarket, 12 
Suffolk, CB8 7UU, UK 13 
5 Broadleys Veterinary Hospital, Craig Leith Road, Stirling, FK7 7LE, UK 14 
6 Diagnostic Laboratory Services, Department of Pathobiology and Population Sciences, Royal 15 
Veterinary College, North Mymms, Hertfordshire, AL9 7TA, UK 16 
 17 
 18 
ABSTRACT 19 
Case series summary: a retrospective multicentre case series of feline primary erythrocytosis (PE) was 20 
evaluated. The aim was to gain better understanding of disease presentation and progression to guide 21 
management and prognostication. Case records were assessed for evidence of increased packed cell 22 
volume (PCV >48%), sufficient investigation to rule out relative and secondary erythrocytosis, and 23 
follow-up data for at least twelve months or until death. Eighteen cats were included in the case series. 24 
No significant trends in signalment were noted. Seizures and mentation changes were the most 25 
common presenting signs (both n = 10). Median PCV was 70% (median total protein concentration of 26 
76g/l) with no other consistent haematological changes. Sixteen cats survived to discharge. 27 
Phlebotomy was performed initially in 15/16 surviving animals and performed after discharge in 28 
10/16. Hydroxyurea was the most common adjunctive therapy, used in 10/16 cats. Of the 16 patients 29 
surviving to discharge, 14 patients were still alive at the conclusion of the study (survival time > 17 30 
months post-discharge), with the two non-survivors having lived for five years or more after diagnosis. 31 
PCV when stabilised did not correlate with resolution of clinical signs. 32 
Relevance and novel information: in contrast to perceptions, feline PE was generally well-managed 33 
via a combination of phlebotomy and medical therapy, with evidence of prolonged survival times.  The 34 
use of hydroxyurea enabled cessation or repeat phlebotomies.  35 
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INTRODUCTION 44 
Feline primary erythrocytosis (PE), also known as polycythaemia, is a rare myeloproliferative disorder 45 
resulting in increased red blood cell mass.(1) It is caused by an erythropoietin-independent clonal 46 
expansion of a single haematopoietic stem cell(1) and in humans is considered a form of 47 
myeloproliferative neoplasm.(2)  48 
Excessive erythropoiesis is suspected to be caused by mutations in the erythropoietic signalling 49 
cascade, resulting in constitutive downstream activation.(3) In humans, the main mutation responsible 50 
for primary polycythaemia (PP) is well-characterised. Ninety-eight percent of human PP is linked to 51 
mutations in Janus Kinase 2 (JAK2), a tyrosine kinase,(4) of which 95% are a valine to phenylalanine 52 
substitution(5) in exon 14 of the JAK2V617F gene.(6,7,8) An identical mutation has also been identified in 53 
a dog with PE.(9) 54 
Affected animals may present acutely with severe signs, often including seizure activity,(1,10) and may 55 
require intensive initial support. Clinicians therefore need to provide rapid information to owners 56 
regarding the morbidity and mortality of this condition. Current knowledge of feline PE is based on 57 
isolated case reports and whilst prognosis is given as 'guarded', survival times of up to six years have 58 
been reported.(1) 59 
The aim of this case series was to collate the largest set of data on feline PE so far, and thereby provide 60 
a comprehensive description of the disease course and possible treatment options to guide 61 
practitioners.  62 
CASE SERIES SUMMARY 63 
Patient records of client-owned cats diagnosed with feline PE from January 2006 to October 2015 64 
were requested from veterinary hospitals across the UK. Five centres provided a total of eighteen 65 
cases: Royal Veterinary College, London (10 cases); Willows, Solihull (4 cases); Animal Health Trust, 66 
Newmarket (2 cases); Vets Now, Glasgow (1 case); Goddard's Veterinary Group, London (1 case).  67 
Diagnosis of PE was based on marked increase in PCV (>48%)(1) with exclusion of relative erythrocytosis 68 
or other secondary causes, such as underlying diseases resulting in hypoxia (e.g. cardiac disease) or 69 
the potential for inappropriate erythropoietin production (e.g. productive renal tumour)(11). 70 
Histories, initial clinical examination and laboratory results were reviewed. Treatment protocols and 71 
further clinicopathological results were assessed during the period of hospitalisation. Follow-up 72 
information was obtained via email or telephone requests, including details of further treatment, on-73 
going clinical signs, changes in haematological values, and survival at time of data collection. 74 
Signalment 75 
Eight cats were female and 10 were male, all were neutered. The median age was 5 years and 7 76 
months (range 35 – 126 months). Median body weight was 4.63 kg (range 2.6-6.4 kg). The majority of 77 
patients were domestic short haired cats (15/18). One cat had been successfully treated for immune-78 
mediated haemolytic anaemia (IMHA, suspected primary) one year prior to presentation, and one cat 79 
had been treated for eosinophilic granuloma complex many years previously: neither were receiving 80 
medication at time of diagnosis. The remainder were reported as having unremarkable previous 81 
medical histories. A summary of the cases can be found in the online supplementary material 82 
(Appendix 1). 83 
Presenting signs and clinical examination 84 
Presenting clinical signs are detailed in Table 1. Neurological signs were the most common presenting 85 
complaint, affecting 16/18 patients, followed by gastrointestinal signs (6/18). The median average 86 
duration of clinical signs prior to presentation was 2 days (range 1 - 167 days). Physical examination 87 
findings are listed in Table 2, with the most notable finding being congested mucous membranes. 88 
Clinicopathological data (at presentation) 89 
Median PCV at presentation was 70% (range 64 - 83%) with a total protein (TP) concentration of 76g/l 90 
(range 51 - 90g/l). All cases with an available complete blood cell count demonstrated increased red 91 
blood cell concentration, haemoglobin concentration and haematocrit. Low mean cell haemoglobin 92 
(9/15) and lymphopenia (10/15) were the other frequent changes seen on haemogram (for more 93 
information, see Appendix 2). Evidence of increased erythrocyte production (e.g. anisocytosis, 94 
polychromasia, and rubricytosis) was frequently seen on blood smear analysis.  95 
Serum biochemistry results were predominantly within reference limits (10/17).(a) Increased 96 
creatinine kinase (CK) activity was present in eight animals (range 525 – 103351 IU/l, reference interval 97 
[RI]: 52 - 506) and three cases had increased urea concentration (range 12.7 - 25.0 mmol/l, RI: 6.1 - 98 
12.0). Four cats (unknown number tested) were reported to have evidence of hypoglycaemia on 99 
patient-side testing: unfortunately numerical values were not recorded. Arterial blood gas analysis 100 
was only performed in two patients, neither of which revealed hypoxemia. 101 
Further laboratory testing included erythropoietin (EPO) assay (n = 11), retroviral testing (n = 8), 102 
thyroxine assay (n = 1), urinalysis (n = 8) and urine culture (n = 2). EPO levels were within given 103 
laboratory reference intervals in 7/11 cats, low in 2 cats and not reported in 2 patients. Seven out of 104 
eight cats were negative on in-house lateral flow immunochromatography retroviral testing (result 105 
not reported in 1 patient) and T4 level was within reference limits for the single cat tested. The only 106 
abnormalities documented on urinalysis were microscopic haematuria in 4 cats and growth of 107 
Escherichia coli from the urine of one cat. Non-invasive blood pressure was measured in 6 cats: all 108 
were normotensive (range  95-142 mmHg). 109 
Diagnostic imaging 110 
A summary of diagnostic imaging modalities and findings is presented in Table 3. Two cats were 111 
euthanased prior to full diagnostic imaging but underwent full post-mortem examination. No 112 
abnormal findings on imaging or post-mortem were considered sufficient to cause secondary PE via 113 
increased EPO production (appropriate or inappropriate). For example, renal lesions documented on 114 
ultrasound were not considered consistent with pathology likely to induce excessive EPO production. 115 
Similarly, degrees of cardiac functional impairment were considered minimal, and certainly 116 
insufficient to cause hypoxaemia, in all cats. No thoracic abnormalities were documented on imaging 117 
in any cats. 118 
Initial management and outcome 119 
One cat was euthanized on the day of presentation due to severity of clinical signs (collapse and 120 
respiratory distress) and one cat was treated purely for seizures, with erythrocytosis only diagnosed 121 
retrospectively. Stabilisation of the erythrocytosis was therefore attempted in 16 cats.  122 
All 16 cases underwent phlebotomy under sedation within 24 hours of presentation. Median volume 123 
of blood removed was 12.5ml/kg (range 4.5-17.9 ml/kg). Eight cats required a second phlebotomy 124 
during hospitalisation to achieve clinical stabilisation and sufficient PCV reduction (aiming for PCV <50-125 
55%). Median total volume of blood removed was therefore 19.5ml/kg (range 4.6-27.5 ml/kg). No 126 
adverse events were reported. 127 
Three cats commenced treatment with hydroxyurea (HU) during the initial hospitalisation period. 128 
Dosages varied from 32mg/kg per os (PO) once daily to 100mg/kg PO every five days. Anti-epileptic 129 
medication was started on presentation in five cats: levetiracetam (n = 3), phenobarbital (n = 1), or 130 
both drugs (n = 1). One cat underwent splenectomy. 131 
Sixteen of 17 cats survived to discharge. The remaining cat was euthanized after two days of 132 
hospitalisation due to owner concerns over reported poor prognosis and quality of life with on-going 133 
treatment. The average time of hospitalisation was six days (range: 1 - 16 days). 134 
 On-going treatment 135 
A variety of treatments were used to reduce PCV and manage clinical signs of PE long-term, as shown 136 
in Table 4 (a more detailed outline of treatment modalities is provided in Appendix 3). Treatment was 137 
usually deemed successful by the attending veterinarian when no clinical signs were seen with a PCV 138 
<60%.  139 
Phlebotomy post-discharge was performed in 10/16 cats over a median time frame of 16.4 months 140 
(range 3-44 months), although one cat (Case 2) only had a single phlebotomy performed 44 months 141 
post-discharge. The median number of phlebotomies performed post-discharge was 7 (range 1-37), 142 
with an average interval of 6.5 weeks (range 1.5-16 weeks). One cat (Case 11) underwent 37 143 
phlebotomies over a period of 18 months, gradually increasing in interval from weekly (1.5-5ml/kg) 144 
up to monthly (3-6ml/kg), and was able to undergo conscious draining on a number of occasions owing 145 
to amenable temperament. Six cats eventually maintained a stable PCV without further phlebotomies 146 
after a variable period of time (range 3-24 months). Mild side effects were intermittently reported, 147 
including difficulty to extract blood due to increased blood viscosity and progressive sclerosis of 148 
jugular veins. 149 
Ten cats received treatment with HU, most commencing in the first month after diagnosis. Initial doses 150 
ranged from 9mg/kg PO once daily to 113mg/kg PO every five days,(b) with titration dependent on 151 
sequential PCV and haematology results. The median stable dose was 22mg/kg PO every other day 152 
(range 10mg/kg SID to 45mg/kg every other day). All cats receiving HU were able to stop phlebotomy 153 
treatment, either immediately or within five months of starting therapy. 154 
Side effects of HU were reported in 6/10 treated cases. Methaemoglobinaemia was reported in three 155 
cats, with symptoms including dyspnoea, tachypnoea, and cyanosis. These cats had received doses at 156 
the upper end of the dose range (>100mg/kg per dose), with signs seen after first dose administration. 157 
Symptoms responded to oxygen supplementation and N-acetylcysteine administration. Dose 158 
reduction and S-adenosylmethionine were effective in preventing recurrence. Evidence of oxidative 159 
damage to haemoglobin was documented in 3 cats (Heinz bodies ranged 30-48%). Four cats also 160 
demonstrated evidence of myelosuppression, with neutropenia in three cats and thrombocytopenia 161 
in one case. Neutropenia was mild in 2 cats (2.46x109/l and 2.21x109/l, RI 2.50 - 12.50) and moderate 162 
in 1 cat (1.78x109/l). The cats with mild neutropenia were receiving 35-45mg/kg on alternate days, 163 
whilst the cat demonstrating moderate neutropenia was receiving 12.5mg/kg daily. 164 
Thrombocytopenia was moderate in the affected cat (56x109/l, RI: 200-600), who was receiving 165 
20mg/kg HU daily. In all cases, concentrations normalised after reduction of HU dose (either by 50% 166 
or by moving to alternate day dosing).  167 
Hirudotherapy (leech treatment) was attempted in three cats. In one patient (Case 3), treatment 168 
appeared to cause pain and triggered seizure activity. In the other patient (Case 7), hirudotherapy was 169 
performed twice with no obvious side effects, but provided insufficient reduction in PCV. Six cases 170 
required anti-epileptic therapy, which was continued long-term in three cats due to on-going seizure 171 
activity. Phenobarbital was used in two cases, levetiracetam in three cases (one discontinued after 172 
two months) and both drugs in Case 12: this cat was receiving no additional treatment for 173 
erythrocytosis. One patient (Case 3) was prescribed aspirin (0.5mg/kg PO once daily) due to 174 
development of thrombocytosis. 175 
On-going monitoring 176 
All cats surviving to discharge had at least 17 months of follow-up data. Fifteen patients demonstrated 177 
reduction of PCV from presentation over the course of treatment (mean reduction 16%, range 3 - 178 
32%).  Details of PCV changes for Case 9 were not available. There was no standardised frequency of 179 
monitoring. 180 
Thrombocytosis (PLT >800x109/l) was reported in three cases. One cat exhibited intermittently 181 
increased platelet concentration from diagnosis onwards for the two and a half years of follow-up 182 
data available, up to a maximum of 1176x109/l. Two cats developed intermittent thrombocytosis five 183 
months post-discharge, rising to a maximum of 1360x109/l. 184 
Leucocytosis occurred in two of the 16 surviving cases. One case (Case 17) developed a transient mild 185 
lymphocytosis (8.4x109/l, RI: 0.2-5.4) two years after diagnosis. This patient was found to have 186 
concurrent Toxoplasma gondii infection. Case 1 developed marked, inappropriate rubricytosis with 187 
the presence of circulating erythroblasts and occasional abnormal myeloid precursors 60 months post-188 
discharge, raising suspicions of a leukaemic transformation. The patient developed marked weight 189 
loss and polyphagia and was euthanased due to concerns regarding prognosis and quality of life. 190 
Long-term Survival 191 
One case (Case 1) was euthanased 5 years after diagnosis due to potential leukaemia, and a further 192 
cat (Case 2) died 4.75 years post-diagnosis, with comorbidities including chronic kidney disease and 193 
senile behavioural changes. Of the 14 remaining cases, all were alive at the time of data collection. 194 
Survival time post-discharge is shown in Table 4. 195 
Continued clinical signs were reported in five cases: seizures (n = 3), periodic mentation changes (n = 196 
1), and development of hind limb ataxia (n = 1). The ataxic patient was additionally diagnosed with 197 
toxoplasmosis, and so it is possible that residual clinical signs were not related to PE. A total of seven 198 
cats achieved a PCV below 50%. Of these, two experienced continued seizures. Of the nine cats with 199 
a stable PCV >50% three experienced on-going clinical signs, whilst the remaining six cats were 200 
asymptomatic. The mean PCV of cats with long-term clinical signs was 46%, compared to 62% for those 201 
with no long-term signs. All cats with on-going clinical signs were perceived to still have a good quality 202 
of life by their owners. 203 
DISCUSSION 204 
Neurological signs have previously been reported as a common presenting complaint in erythrocytotic 205 
cats.(1,10,11) Incidence in this case series was 14/16 cats, slightly higher than previous estimations of 50-206 
87%.(1,10) Erythrocytosis is therefore a possible, if rare, differential for acute onset seizures in the cat. 207 
The suspected aetiology is cerebral hypoglycaemia(12) or hypoxia with possible ischaemic episodes, as 208 
cerebral blood flow is known to be reduced in humans once PCV exceeds 46-52%.(13)  209 
Imaging and laboratory findings were similar to those reported in the literature.(1,11) A number of the 210 
most common changes included increased CK activity, hypoglycaemia and left ventricular 211 
hypertrophy. Increased CK activity may be caused by ischaemic myopathy or thrombotic events. 212 
Hypoglycaemia is known to occur with increased PCV due to decreased plasma volume for glucose 213 
transport,(12) and post-sampling due to increased glucose metabolism in vitro by erythrocytes.(14) 214 
Point-of-care glucometers have been documented to give lower results than reference analysers, 215 
however these differences tend to be of minimal clinical significance, and therefore may not account 216 
for the hypoglycaemia documented here.(15) Low fructosamine values are likely to be more reflective 217 
of true chronic hypoglycaemia than direct glucose measurements in PE patients. There is known to be 218 
a significant overlap in EPO values between normal cats and those with both primary and secondary 219 
erythrocytosis.(16) EPO assay is therefore deemed to be of limited use in diagnosing PE. Mild ventricular 220 
hypertrophy was present in four cats (31% of those undergoing echocardiography), and may be 221 
incidental, or could reflect compensatory hypertrophy due to increased cardiac work-load due to 222 
increased blood viscosity. 223 
Phlebotomy has always been the key treatment of an acutely presenting erythrocytotic patient,(13) 224 
rapidly improving clinical signs.  The average amount of blood removed to achieve in this case series 225 
was 19.5ml/kg, equating to a reduction in PCV of approximately 15%.(17) Intermittent phlebotomy can 226 
be continued long-term, with frequency determined by regular monitoring of PCV and clinical signs. 227 
Potential side effects of phlebotomy include hypoferritaemia, hypoproteinaemia, sedation risks, 228 
venous thrombosis(3)and patient stress, in addition to financial and time investment by the owner. 229 
If phlebotomy is required at an unacceptable frequency or side effects are noted, medical therapy in 230 
the form of HU should be considered. HU is a ribonucleotide reductase inhibitor, reducing cellular 231 
proliferation by interfering with the de novo synthesis of deoxyribonucleotides.(18) HU also inhibits 232 
recycling of methaemoglobin back to haemoglobin and can result in a significant increase in 233 
methaemoglobin levels, usually maintained at 1%.(19) Dyspnoea occurs when this level exceeds 25%.(19) 234 
Additionally, inhibition of DNA synthesis can cause reversible bone marrow suppression.(11) The data 235 
from this case series suggests that lower doses at a more regular frequency are associated with 236 
reduced incidence of symptomatic methaemoglobinaemia. Starting cats on daily or alternate day 237 
dosing and maintaining long-term dose at less than 20-30mg/kg HU PO per day (or alternate day 238 
dosing) is therefore advisable.  239 
Previous literature has advised to aim for a stable PCV of less than 50%.(1) This was only achieved in 240 
7/16 of patients in this study, however 6/9 remaining cats were asymptomatic long-term. The average 241 
stable PCV was in fact higher in cats without on-going clinicial signs than those with continued signs. 242 
It is therefore not possible to suggest a new therapeutic target from this data, however it would 243 
appear that PCV <50% is an unnecessarily low goal.  244 
Only two cats appeared to achieve remission, defined in human medicine as clinical and 245 
haematological resolution without intervention for at least three months.(20) At present, a clear 246 
dialogue should be maintained with the owners to discuss the difference between achieving clinical 247 
and haematological control of the disease when deciding thresholds for intervention.  248 
This study suggests that feline PE has a good prognosis for survival, with survival times of up to, and 249 
possibly exceeding, 5 years. Cats also maintain a good quality of life, with the patients in this case 250 
series either becoming asymptomatic or experiencing readily controlled clinical signs (e.g. seizures 251 
managed with anti-epileptic medication). 252 
Human literature reports 3-19% incidence of progression of PV to acute leukaemia, and 5-14% 253 
incidence of transformation to myelofibrosis.(21) One cat demonstrated possible malignant 254 
transformation, however this was not confirmed with bone marrow examination. Longer-term follow-255 
up data would be required to determine the risk of malignant transformation. 256 
A notable difference between feline PE and the most common form of human PP is the absence of 257 
consistent trilineage hypercellularity in cats. Thrombocytosis and leucocytosis were documented in 258 
this case series in only a handful of patients, with neither abnormality occurring concurrently. This 259 
casts doubt on the likelihood of the prominent human JAK2V617F mutation as the underlying genetic 260 
cause. However, erythrocytosis is known to occur as the only haematological abnormality in a subset 261 
of gain-of-function JAK2 mutations affecting exon 12 as opposed to exon 14.(21,22) This is believed to 262 
be the genetic cause of PP in approximately 3% of human patients.(23) Congenital erythrocytosis, 263 
suspected to be caused by a truncated EPO receptor,(4,24) also causes pure erythrocytosis, however the 264 
signalment of patients in this study is not supportive of a congenital basis for feline PE. JAK2 is now a 265 
target for novel medical treatments for polycythaemia. Ruxolitinib, a JAK1 and JAK2 inhibitor, appears 266 
to be well-tolerated, and a study comparing efficacy in humans with HU therapy has recently been 267 
completed (the RELIEF trial).(13)   268 
CONCLUSIONS 269 
This study  provides information to aid practitioners in diagnosing and managing cases of feline 270 
erythrocytosis. Importantly, it should be noted that the historic term 'polycythaemia' is a misnomer: 271 
'erythrocytosis' is a more accurate name, reflecting the lack of multilineage hypercellularity in this 272 
species. 273 
In contrast to previous literature, this case series suggests a good outcome for treated cats in the 274 
medium to long-term. Phlebotomy is required for immediate cytoreduction and can be combined 275 
with, or supplanted by, medical therapy. Elucidation of the underlying cause of feline erythrocytosis 276 
would likely result in novel targets for treatment, possibly with improved reduction in PCV and 277 
reduced adverse effects. This would require genetic comparison between affected and unaffected 278 
animals. Extrapolation from human medicine suggests that JAK2, with a possible focus on exon 12, 279 
could prove fruitful ground for further investigation. 280 
 281 
FOOTNOTES: 282 
a. Quoted reference intervals are those of the Diagnostic Laboratory Services from the Royal 283 
Veterinary College 284 
b. Reformulated hydroxyurea capsules and a liquid formulation are available, which can facilitate 285 
administration of smaller doses 286 
 287 
SUPPLEMENTARY MATERIALS (Appendices): 288 
APPENDIX 1: summary of feline PE cases (n = 18) 289 
APPENDIX 2: common haematological changes in feline PE cases 290 
APPENDIX 3: long-term treatment and survival data for feline PE cases 291 
 292 
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For Peer Review
Clinical sign Number affected (/18) 
Seizures 
- generalised 
- focal  
10 
- 8 
- 2 
Altered mentation 10 
Tremors/twitching 
- facial 
- pelvic limbs 
6 
- 6 
- 1 
Ataxia 6 
Circling 5 
Weakness 5 
Respiratory distress 
- mild 
- moderate  
5 
- 2 
- 3 
Vomiting 
- haematemesis 
3 
- 2 
Ptyalism 3 
Polyphagia 3 
Blindness 2 
Personality changes 2 
Pelvic limb stiffness 2 
Pica 2 
Diarrhoea 1 
Haematochezia 1 
Inappetence 1 
Polydipsia 1 
Weight loss 1 
Table 1: Presenting clinical signs in feline PE cases 
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Physical examination 
finding 
Number affected (/18) 
Congested mucous 
membranes 
11 
Hyperthermia  
(range 39.2oC - 41.4oC) 
4 
Reduced / absent menace 
response 
4 
Hippus 2 
Delayed pupillary light 
reflexes 
1 
Nystagmus 1 
Bruising 1 
Peripheral venous dilation 1 
Cutaneous erythema 1 
Table 2: Physical examination findings on presentation in feline PE cases 
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Imaging modality Number 
(/18) 
Findings 
Abdominal 
ultrasound 
16 Unremarkable = 7 
Chronic nephropathy = 4 
Enteropathy = 3 
Hepatopathy = 2 
Splenomegaly = 2 
Thoracic 
radiography 
14 Unremarkable = 14 
CT 2 Unremarkable = 1 
Chronic nephropathy = 1 
 
Echocardiography 13 Unremarkable = 9 
Mild left ventricular hypertrophy = 4 
Borderline left atrial enlargement = 2 
MRI 2 Hippocampal oedema / necrosis = 2 (likely secondary to 
seizure activity) 
Table 3: Imaging modalities and findings in feline PE patients 
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Case Maintenance 
treatment 
Stable PCV 
(%) 
Able to stop 
treatment 
Continued 
clinical signs 
Perceived 
quality of 
life 
Survival time 
(months) 
1. 5y DSH 
(FN) 
HU 30 - 50 Yes None Good 64  
(PTS) 
2. 8y DSH 
(MN) 
HU 59 Yes None Good 57  
(died) 
3. 5y4m 
DLH (MN) 
Phlebotomy, 
anti-
epileptics, 
aspirin 
37 Yes Seizures Fair >40  
(alive) 
6. 6y1m 
DSH (MN) 
Phlebotomy 60-70 No None Good >30  
(alive) 
7. 2y11m 
BSH (MN) 
HU, 
phlebotomy, 
anti-epileptics 
38 No Seizures Good >25  
(alive) 
8. 5y DSH 
(MN) 
HU, 
phlebotomy, 
anti-epileptics 
62 No Intermittent 
lethargy and 
disorientation 
Good >19  
(ali e) 
9. 8y11m 
DSH (MN) 
Phlebotomy, 
clopidogrel 
(Unknown) No None Good >17  
(alive) 
10. 6y DSH 
(FN) 
HU 48 No None Good >17  
(alive) 
11. 5y 
Maine 
Coon (FN) 
Phlebotomy 40-50 Yes None Good >62  
(alive) 
12. 6y DSH 
(MN) 
Anti-epileptics (Unknown) N/A Seizures Good >22  
(alive) 
13. 6y9m HU (Unknown) Unknown None Good >55  
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DSH (MN) (alive) 
14. 4y6m 
DSH (FN) 
HU, anti-
epileptics 
55-60 No None Good >24  
(alive) 
15. 8y7m 
DSH (FN) 
HU 55-60 No None Good >22  
(alive) 
16. 6y DSH 
(FN) 
HU 54 No None Good >47  
(alive) 
17. 10y6m 
DSH (MN) 
HU 48 No Ataxia Fair >44  
(alive) 
18. 4y DSH 
(FN) 
HU, 
phlebotomy 
(Unknown) No None 
 
Good >27  
(alive) 
Table 4: Long-term follow up data of feline PE cases. Cases 4 & 5 did not survive to initial discharge and are therefore not included. 
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Case Presenting 
signs 
Physical 
examination 
findings 
Initial  
PCV / TP 
Initial 
treatment 
Survival to 
discharge 
Maintenance 
treatment 
Able to 
cease 
treatment 
Survival 
time 
(months) 
1. 5y DSH 
(FN) 
Facial 
twitching, 
manic 
behaviour (1d) 
Congested 
mucous 
membranes, 
depressed 
68 / 70 Phlebotomy Yes HU Yes 64 (PTS) 
2. 8y DSH 
(MN) 
Seizures, 
twitching, 
circling, 
polydipsia, 
polyphagia (4d) 
 76 / 90 Phlebotomy Yes HU Yes 57 (died) 
3. 5y4m 
DLH (MN) 
Seizures, 
hyperaesthesia, 
polyphagia, 
vomiting, 
diarrhoea (4d) 
Mild urinary 
retention 
69 / 77 Phlebotomy Yes Phlebotomy, 
anti-
epileptics, 
aspirin 
Yes >40 (alive) 
4. 3y10m 
DSH (MN) 
Collapse, 
respiratory 
distress (2d) 
Congested 
mucous 
membranes, 
obtundation, 
diffuse 
pulmonary 
crackles 
83 / 76 None No N/A N/A N/A 
5. 4y1m 
DSH (FN) 
Seizures, ataxia 
(1d) 
Obtundation, 
dehydration 
78 / - Phlebotomy No N/A N/A N/A 
6. 6y1m 
DSH (MN) 
Seizures, 
weakness (1d) 
Obtundation, 
heart murmur 
70 / 67 Phlebotomy Yes Phlebotomy No >30 (alive) 
7. 2y11m 
BSH (MN) 
Seizures (28d) Tachypnoea, 
circling, 
proprioceptive 
deficits 
67 / 60 Phlebotomy Yes HU, 
phlebotomy, 
anti-
epileptics 
No >25 (alive) 
8. 5y DSH 
(MN) 
Stupor, facial 
twitching (2d) 
Blind, gallop 
rhythm 
76 / 90 Phlebotomy Yes HU, 
phlebotomy, 
anti-
epileptics 
No >19 (alive) 
9. 8y11m 
DSH (MN) 
Stiffness, 
haematochezia 
Heart murmur, 
increased 
67 / 78 Phlebotomy Yes Phlebotomy, 
clopidogrel 
No >17 (alive) 
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(2d) bronchovesicular 
sounds 
10. 6y DSH 
(FN) 
Weight loss, 
haematemesis, 
pica (6d) 
Unremarkable 64 / 70 Phlebotomy Yes HU No >17 (alive) 
11. 5y 
Maine 
Coon (FN) 
Ataxia, circling 
(1d) 
Unilateral 
menace deficit 
65 / 51 Phlebotomy Yes Phlebotomy Yes >62 (alive) 
12. 6y DSH 
(MN) 
Focal seizures, 
aggression (7d) 
Aggressive 71 / - None Yes Anti-
epileptics 
N/A >22 (alive) 
13. 6y9m 
DSH (MN) 
Seizures (1d) Dull, congested 
mucous 
membranes 
80 / - Phlebotomy Yes HU Unknown >55 (alive) 
14. 4y6m 
DSH (FN) 
Seizures, 
ataxia, 
ptyalism, facial 
twitching (41d) 
Congested 
mucous 
membranes, 
hyperthermia 
65 / 69 Phlebotomy Yes HU, anti-
epileptics 
No >24 (alive) 
15. 8y7m 
DSH (FN) 
Circling (1d) Dyspnoea, 
generalised 
erythema 
70 / 76 Phlebotomy Yes HU No >22 (alive) 
16. 6y DSH 
(FN) 
Seizures, head 
tremors (1d) 
Congested 
mucous 
membranes, 
abdominal pain 
70 / 72 Phlebotomy Yes HU No >47 (alive) 
17. 10y6m 
DSH (MN) 
Pelvic limb 
ataxia, 
haematochezia, 
haematuria 
(167d) 
Muscle atrophy, 
plantigrade 
stance 
55 / 70 Phlebotomy Yes HU No >44 (alive) 
18. 4y DSH 
(FN) 
Pelvic limb 
ataxia, 
weakness, 
lethargy 
Heart murmur, 
stiffness, 
tachypnoea 
75 / - Phlebotomy Yes HU, 
phlebotomy 
No >27 (alive) 
Appendix 1: summary of feline PE cases 
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Parameter Change and frequency Median value (range) Reference intervals (SI units) 
RBC ↑ (15/15) 17.30 (13.40 - 22.36) 5.0 - 10.0 (x10
12
/l) 
HGB ↑ (15/15) 21.5 (18.2 - 27.5) 8.0 - 15.0 (g/dL) 
HCT ↑ (15/15) 65.9 (54 - 84.5) 24.0 - 45.0 (%) 
MCH ↓ (9/15) 12.6 (9.7 - 15.1) 13.0 - 17.5 (pg) 
Lymphocytes ↓ (10/15) 1.42 (0.17 - 4.4) 2.5 - 12.4 (x10
9
/l) 
Appendix 2 : Common haematological changes in feline PE cases. Machine used: Advia 2021i. Reference intervals used: 
QMHA laboratory. RBC: red blood cell count, HGB: haemoglobin concentration, HCT: haematocrit; MCH: mean cell 
haemoglobin 
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Case 
Number 
Phlebotomy Hydroxyurea Other 
medication 
Stable 
PCV 
Clinical signs Perceived 
quality of 
life 
Survival 
time 
(months) 
 Number 
post- 
discharge 
Interval 
post-
discharge 
(weeks) 
Overall 
time post-
discharge 
(months) 
Stopped or 
on-going 
Initial dose Maintenance 
dose 
Side effects      
1 0 N/A 0 Stopped 113mg/kg 
q4d 
 
23-45mg/kg 
EOD 
Stopped after 
46mo 
Initial MMB,  
Heinz bodies, 
transient mild 
neutropaenia 
None 30-50 None Good 64 
2 1 (Once) 44 Stopped 100mg/kg 
q5d 
30mg/kg EOD Initial MMB  None 59 None Good 58 
3 5 2-3 4 
 
Stopped 
 
N/A N/A N/A PB 37 Seizures Fair >40 
6 18 6 29 On-going 
 
N/A N/A N/A None 60-70 None Good >29 
7 5 2 3 Stopped 35mg/kg 
EOD 
19mg/kg EOD Heinz bodies, 
transient mild 
neutropaenia  
PB 38 Intermittent 
seizures 
Good >25 
8 5 10 13 On-going 15mg/kg  
SID 
20mg/kg SID None None 62 Intermittent 
lethargy and 
disorientation 
Good >19 
9 Unknown Unknown Unknown Unknown N/A N/A N/A None Unknown None Good >17 
10 2 6 3 Stopped 
 
10mg/kg 
SID 
10mg/kg SID None Renal diet 48 None Good >17 
11 37 1-2 14mo Stopped N/A N/A N/A None 40-50 None Good >62 
12 0 N/A 0 N/A N/A N/A N/A PB, leve Unknown Intermittent Good >22 
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seizures 
13 Unknown Unknown 24 Stopped 100mg/kg 
q5d 
25mg/kg SID  
Stopped after 
24mo 
Initial MMB None Unknown None Good >55 
14 0 N/A 0 N/A 10mg/kg 
SID  
10mg/kg SID 
Stopped after 
4mo 
None None 55-60 None Good >24 
15 4 16 18 On-going 10mg/kg 
SID 
9mg/kg BID None Meloxicam 55-65 None Good >22 
16 0 N/A 0 N/A 17mg/kg 
SID 
17mg/kg EOD Transient 
moderate 
thrombocyto-
paenia 
None 54 None Good >47 
17 0 N/A 0 N/A 15mg/kg 
SID 
15mg/kg SID None None 48 Ataxia Fair/good >44 
18 6 8 12 Stopped 32mg/kg 
q3d 
13mg/kg SID Transient 
moderate 
neutropaenia 
None Unknown None Good >27 
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